SCHEMBL289028

SCHEMBL289028

O=C(c1cccc(C(F)(F)F)c1)c1coc2c(Br)c(Br)c(O)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.44
CES2 O00748 1/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
CNR1 P21554 1/20 0.43
PTGS2 P35354 1/20 0.43
SIRT1 Q96EB6 1/20 0.41
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
CNR2 P34972 3/20 0.40
TLR7 Q9NYK1 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
POLB P06746 2/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PTBP1 P26599 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290323 0.82 PTGS2 (0.56) RAB9ANPC1PTGS2SIRT1ALOX15
SCHEMBL290558 0.82 RAB9A (0.45) RAB9ANPC1PTGS2SIRT1CNR2
SCHEMBL290295 0.78 PTGS2 (0.51) RAB9ANPC1PTGS2SIRT1KMT2A
SCHEMBL290225 0.76 PTGS2 (0.52) SRD5A2RAB9ANPC1PTGS2SIRT1
SCHEMBL290073 0.76 PTGS2 (0.52) SRD5A2RAB9ANPC1PTGS2SIRT1
SCHEMBL290149 0.74 PTGS2 (0.44) CES2RAB9ANPC1PTGS2SIRT1
SCHEMBL299578 0.73 SRD5A2 (0.46) SRD5A2RAB9ANPC1PTGS2KMT2A
SCHEMBL299187 0.73 PTGS2 (0.44) RAB9ANPC1PTGS2KMT2AMEN1
SCHEMBL290525 0.73 PDF (0.53) RAB9ANPC1PTGS2SIRT1KMT2A
SCHEMBL289532 0.72 NPC1 (0.57) RAB9ANPC1PTGS2SIRT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2959898-A1 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2015-12-30 EP disclosed
EP-2427057-B1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN KETTERING INST CANCER (US) 2015-08-12 EP disclosed
US-8614237-B2 Benzofuran-4,5-diones as selective peptide deformylase inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-12-24 US disclosed
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed
EP-2427057-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2012-03-14 EP disclosed
WO-2010129049-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS PDF, EIF5B, EIF4E SRD5A2 2223/4885CES2 4261/4885RAB9A 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.